87913-26-6

Basic information

• Product Name: N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE
• Synonyms: 2-(4-BROMOPHENYL)AMINOADAMANTANE;AKOS BB-9852;N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE;bromantan;bromantane;n-(4-bromophenyl)-tricyclo(3.3.1.1(sup3.7))decan-2-amin;N-(4-BroMophenyl)tricyclo[3.3.1.13,7]decan-2-aMine;Tricyclo[3.3.1.13,7]decan-2-aMine,N-(4-broMophenyl)-
• CAS NO: 87913-26-6
• Molecular Formula: C₁₆H₂₀BrN
• Molecular Weight: 306.24
• Product Categories: Adamantane derivatives;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 87913-26-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 404.8 °C at 760 mmHg
• Flash Point: 198.6 °C
• Appearance: /
• Density: 1.388±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: 3.97±0.20(Predicted)
• CAS DataBase Reference: N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE(87913-26-6)
• EPA Substance Registry System: N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE(87913-26-6)

Safety Data

• Hazardous Substances Data: 87913-26-6(Hazardous Substances Data)

Usage

Description

N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE, also known as Bromantane, is an adamantane derivative featuring a bromaniline side chain. It has been utilized therapeutically in Russia as a psychostimulant and anxiolytic, exhibiting serotonergic, dopaminergic, and limited noradrenergic actions, similar to mesocarb. Bromantane was first identified in 1996 but faced legal issues, leading to its inclusion in the IOC list of prohibited substances in September 1996.

Uses

Used in Pharmaceutical Industry:
N-(2-ADAMANTYL)-N-(4-BROMOPHENYL)AMINE is used as an anxiolytic agent for its therapeutic effects in reducing anxiety and stress. Its psychostimulant properties also contribute to its use in enhancing cognitive function and mood regulation.

Side effects

Bromantane is said to have no addictive potential, and research done thus far shows that it doesn’t have serious side effects. Some users have reported having experienced brain fog, depression, and fatigue after the use of Bromantane. Nonetheless, there hasn't been sufficient research on Bromantane. Most of the trials have been conducted on rodents; therefore, its safety in humans is still uncertain.

Upstream product

• 700-58-3 2-Adamantanone 
• 106-40-1 4-bromo-aniline 
• 106-37-6 1.4-dibromobenzene 
• 13074-39-0 N-(2-adamantyl)amine 

Relevant articles and documents

Anthracene-rhodium complexes with metal coordination at the central ring-a new class of catalysts for reductive amination

A new class of anthracene complexes with a metal coordinated at the central ring was applied in catalysis for the first time. As a result, a simple and efficient protocol for reductive amination that involves CO as a reducing agent has been developed. The rhodium complex [(cyclooctadiene)Rh(C10H4Me2(OMe)4)]+ (1 mol%) catalyses such reactions under mild conditions (40-130 °C) and produces a variety of amines in good yields (74-95%) without affecting the functional groups. The protocol is acceptable for all combinations of aldehydes (aromatic and aliphatic), ketones (aromatic and aliphatic) and amines (aromatic and aliphatic; primary and secondary).

Palladium-catalyzed amination of isomeric dihalobenzenes with 1- and 2-aminoadamantanes

Palladium-catalyzed amination of isomeric bromochloro- and dibromobenzenes with 1- and 2-aminoadamantanes was studied. The best yields of the corresponding monoamination products were obtained in the reactions of 2-aminoadamantane with bromochlorobenzenes